Histologic benefits of virologic response to peginterferon alfa-2a monotherapy in patients with hepa

January 21, 2008

Alimentary Pharmacology & Therapeutics (OnlineAccepted Articles).

doi:10.1111/j.1365-2036.2008.03620.x

Abstract

Histologic benefits of virologic response to peginterferon alfa-2a monotherapy

in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

G. T. EVERSON11Section of Hepatology, University of Colorado School of Medicine,

University of Colorado Health Sciences Center, Denver, Colorado, L. BALART22FACG

Section of Gastroenterology, Louisiana State University Health Sciences Center,

New Orleans, Louisiana, S. S. LEE33Faculty of Medicine, University of Calgary,

Calgary, Alberta, Canada, R. W. REINDOLLAR44Carolinas Center for Liver Disease,

Charlotte, North Carolina, M. L. SHIFFMAN55Hepatology Section, Virginia

Commonwealth University Medical Center, Richmond, Virginia, G. Y. MINUK66Section

of Hepatology, Department of Medicine, University of Manitoba, Winnipeg,

Manitoba, Canada, P. J. POCKROS77Division of Gastroenterology/Hepatology, The

Scripps Clinic, La Jolla, California, S. GOVINDARAJAN88Department of Pathology,

Keck School of Medicine, University of Southern California, Los Angeles,

California, E. LENTZ99Roche Laboratories, Nutley, New Jersey & E. J.

HEATHCOTE1010Department of Medicine, University Health Network, Toronto Western

Hospital, Toronto, Ontario, Canada1Section of Hepatology, University of Colorado

School of Medicine, University of Colorado Health Sciences Center, Denver,

Colorado

2FACG Section of Gastroenterology, Louisiana State University Health Sciences

Center, New Orleans, Louisiana

3Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

4Carolinas Center for Liver Disease, Charlotte, North Carolina

5Hepatology Section, Virginia Commonwealth University Medical Center, Richmond,

Virginia

6Section of Hepatology, Department of Medicine, University of Manitoba,

Winnipeg, Manitoba, Canada

7Division of Gastroenterology/Hepatology, The Scripps Clinic, La Jolla,

California

8Department of Pathology, Keck School of Medicine, University of Southern

California, Los Angeles, California

9Roche Laboratories, Nutley, New Jersey

10Department of Medicine, University Health Network, Toronto Western Hospital,

Toronto, Ontario, Canada

Correspondence and/or reprint requests to:

T. Everson, MD, FACP

Section of Hepatology

University of Colorado School of Medicine

University of Colorado Health Sciences Center

UCH AOP, Hepatology Section

1635 N Ursula, B-154

PO Box 6510

Aurora, CO 80045

USA

Telephone: 720-848-2291

Fax: 720-848-2246

Email: greg.everson@...

Summary

Background: Patients with chronic hepatitis C virus (HCV) and advanced fibrosis

or cirrhosis are at risk for disease progression and hepatic decompensation.

Aim: To determine the effects on hepatic histology of treatment with

peginterferon alfa-2a (90 or 180 ìg/wk) or interferon alfa-2a (3 million units 3

times weekly) for 48 weeks in patients with paired biopsies.

Methods: Liver biopsies were obtained at baseline and 6 months after end of

treatment. Histologic and virologic responses were compared.

Results: Patients attaining sustained virologic response (SVR; n=40)

demonstrated the greatest improvements in fibrosis (-1.0, P

_________________________________________________________________

Need to know the score, the latest news, or you need your HotmailR-get your

" fix " .

http://www.msnmobilefix.com/Default.aspx

January 21, 2008